AU1753699A - Application of vasopressin antagonists for treating disturbances or illnesses ofthe inner ear - Google Patents

Application of vasopressin antagonists for treating disturbances or illnesses ofthe inner ear

Info

Publication number
AU1753699A
AU1753699A AU17536/99A AU1753699A AU1753699A AU 1753699 A AU1753699 A AU 1753699A AU 17536/99 A AU17536/99 A AU 17536/99A AU 1753699 A AU1753699 A AU 1753699A AU 1753699 A AU1753699 A AU 1753699A
Authority
AU
Australia
Prior art keywords
illnesses
application
inner ear
antagonists
disturbances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17536/99A
Inventor
Hubert Lowenheim
J. Peter Ruppersberg
Hans Peter Zenner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otogene AG
Original Assignee
Otogene AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7847628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU1753699(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otogene AG filed Critical Otogene AG
Publication of AU1753699A publication Critical patent/AU1753699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The invention relates to the application of at least one vasopressin receptor antagonist or mixture of such antagonists in order to treat disturbances or illnesses of the inner ear. These disturbances/illnesses can be connected to at least one of the following symptoms: vertigo, impairment of hearing or tinnitus. The symptoms can especially relate to those of so-called Ménièr's disease. According to the invention, especially vasopressin V2 receptor antagonists can be applied, whereby the antagonists can be peptidic or non-peptidic substances.
AU17536/99A 1997-11-05 1998-11-04 Application of vasopressin antagonists for treating disturbances or illnesses ofthe inner ear Abandoned AU1753699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19748763 1997-11-05
DE19748763A DE19748763A1 (en) 1997-11-05 1997-11-05 Use of vasopressin antagonists
PCT/EP1998/007033 WO1999024051A2 (en) 1997-11-05 1998-11-04 Application of vasopressin antagonists for treating disturbances or illnesses of the inner ear

Publications (1)

Publication Number Publication Date
AU1753699A true AU1753699A (en) 1999-05-31

Family

ID=7847628

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17536/99A Abandoned AU1753699A (en) 1997-11-05 1998-11-04 Application of vasopressin antagonists for treating disturbances or illnesses ofthe inner ear

Country Status (9)

Country Link
EP (1) EP1028725B1 (en)
JP (1) JP2001522807A (en)
AT (1) ATE259230T1 (en)
AU (1) AU1753699A (en)
BR (1) BR9813957A (en)
CA (1) CA2309117A1 (en)
DE (2) DE19748763A1 (en)
ES (1) ES2218875T3 (en)
WO (1) WO1999024051A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU32702A (en) 1999-11-04 2005-06-10 Ortho-Mcneil Pharmaceutical Inc. Nonpeptide substituted benzothiazepines as vasopressin antagonists
WO2001054698A1 (en) * 2000-01-26 2001-08-02 Warner-Lambert Company Method for preventing or treating postoperative ileus
DE10025152A1 (en) * 2000-05-23 2001-12-06 Marlies Knipper Treatment of noise- or age-induced hearing deficiency, comprises using neurotrophin stimulating agents to counteract cochlear neurodegeneration
US6977254B2 (en) 2001-04-12 2005-12-20 Wyeth Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7109193B2 (en) 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7326700B2 (en) 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US7064120B2 (en) 2001-04-12 2006-06-20 Wyeth Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CA2723458C (en) 2008-05-14 2014-01-28 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
US10092580B2 (en) 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CA2751761A1 (en) 2008-10-22 2010-04-29 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
WO2015031393A1 (en) 2013-08-27 2015-03-05 Otonomy, Inc. Treatment of pediatric otic disorders
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. Otic gel formulations for treating otitis externa

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095003A (en) * 1986-08-13 1992-03-10 Merck & Co., Inc. Oxytocin and vasopressin antagonists
TW354762B (en) * 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract

Also Published As

Publication number Publication date
DE59810761D1 (en) 2004-03-18
WO1999024051A2 (en) 1999-05-20
DE19748763A1 (en) 1999-05-06
CA2309117A1 (en) 1999-05-20
EP1028725B1 (en) 2004-02-11
ES2218875T3 (en) 2004-11-16
BR9813957A (en) 2000-09-26
ATE259230T1 (en) 2004-02-15
JP2001522807A (en) 2001-11-20
EP1028725A1 (en) 2000-08-23
WO1999024051A3 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
AU1753699A (en) Application of vasopressin antagonists for treating disturbances or illnesses ofthe inner ear
ZA965235B (en) Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
MX9706969A (en) 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists.
MX9703186A (en) Indolyl neuropeptide y receptor antagonists.
TR200002773T2 (en) Smilagen and anzurogenin-D and their use for the treatment of Alzheimer's.
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
ATE234092T1 (en) 2-ALKYLPYRROLIDINE
CY2567B1 (en) Treatment of normotensive glaucoma with angiotensin II antagonists
TNSN00010A1 (en) CARBOXYARYL SUBSTITUTED DIPHENYLUREA AS RAF KINASE INHIBITORS.
WO2000006085A3 (en) Compounds and methods
WO1999047131A3 (en) Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
AU4881697A (en) Prevention and treatment of skeletal disorder with EP2 receptor subtype se lective prostaglandin E2 agonists
MXPA02012626A (en) Bis-arylsulfones.
ZA951974B (en) Bradykinin antagonist peptides incorporating N-subsituted glycines
ATE381533T1 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR USE
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
MY127686A (en) Monofluoroalkyl derivatives
DK0946157T3 (en) Topical use of kappa-opioid agonists for the treatment of eye pain
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
ES2132401T3 (en) TETRAHIDRO-1H-BENZAZEPINONAS AND HEXAHIDROAZEPINONAS AS SELECTIVE ANTAGONISTS OF THE COLLECTOSTOKININ-B RECEPTOR.
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
NO20000519L (en) 2-acylaminopropanamines as tachykinin receptor antagonists
PT1000046E (en) ACTIVE PIPERAZINE DERIVATIVES IN LOWER URINARY TRACT
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
TR200001970T2 (en) Triazine compounds for the treatment of MSS disorders.

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted